For Admin
A Leading Company in Nasal Drug Delivery
SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.
3D Nasal Cast Model
Oct 31, 2024
SNBL’s Subsidiary Satsuma Pharmaceuticals Resubmits New Drug Application for STS101 for Acute Treatment of Migraine With or Without Aura
Jan 18, 2024
FDA Issues Complete Response Letter for Satsuma’s STS101
June 26, 2023
SNBL Announces Results of Collaboration Research with Hamamatsu University School of Medicine Using SNBL’s Nose-to-Brain Delivery Technology
May 19, 2023
Satsuma Pharmaceuticals Announces FDA Acceptance of NDA for STS101, a Novel and Investigational DHE Nasal Powder Product for the Acute Treatment of Migraine
April 17, 2023
SNBL Enters into Definitive Agreement to Acquire Satsuma Pharmaceuticals, Inc.
November 24, 2022
SNBL’s Comments on Results from Clinical Phase 3 Studies of STS101, an Investigational Migraine Drug Candidate, Announced by Satsuma Pharmaceuticals, Inc.
November 14, 2022
Satsuma Pharmaceuticals Announces Topline Results from the STS101 SUMMIT Phase 3 Efficacy Trial for the Acute Treatment of Migraine
September 21, 2022
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
August 02, 2021
Satsuma Pharmaceuticals Announces First Subject Randomized in the Phase 3 SUMMIT Efficacy Trial of STS101 for Acute Treatment of Migraine
June 17, 2021
Satsuma Pharmaceuticals, Inc. Announces Positive PK, Tolerability, and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
March 02, 2021
Satsuma Pharmaceuticals, Inc. Announces Updated STS101 Development Plan
September 11, 2020
Satsuma Pharmaceuticals, Inc. Announces Topline Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of Migraine
August 07, 2020
Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND Phase 3 Open-label Trial of STS101 for Acute Treatment of Migraine
June 01, 2020
Satsuma Pharmaceuticals, Inc. Announces Completion of Enrollment for Phase 3 EMERGE Trial of STS101 for Acute Treatment of Migraine
May 19, 2020
Satsuma Pharmaceuticals, Inc. Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform
May 12, 2020
Satsuma Pharmaceuticals, Inc. Reports STS101 Development Progress in its First Quarter 2020 Financial Results
February 03, 2020
Satsuma Pharmaceuticals, Inc. Announces Publication of STS101 Phase 1 Clinical Trial Results in Headache: The Journal of Head and Face Pain
September 17, 2019
Satsuma Pharmaceuticals, Inc. Listed on NASDAQ
August 23, 2019
Satsuma Pharmaceuticals, Inc. Announces First Patient Dosed in EMERGE, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine